Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA222509
Max Phase: Preclinical
Molecular Formula: C23H12Cl2N4O5
Molecular Weight: 495.28
Molecule Type: Small molecule
Associated Items:
ID: ALA222509
Max Phase: Preclinical
Molecular Formula: C23H12Cl2N4O5
Molecular Weight: 495.28
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(O)c1ccc(Nc2nc(Cl)nc(Cl)n2)cc1-c1c2ccc(=O)cc-2oc2cc(O)ccc12
Standard InChI: InChI=1S/C23H12Cl2N4O5/c24-21-27-22(25)29-23(28-21)26-10-1-4-13(20(32)33)16(7-10)19-14-5-2-11(30)8-17(14)34-18-9-12(31)3-6-15(18)19/h1-9,30H,(H,32,33)(H,26,27,28,29)
Standard InChI Key: NJQHZBRWPXRTIW-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 495.28 | Molecular Weight (Monoisotopic): 494.0185 | AlogP: 5.20 | #Rotatable Bonds: 4 |
Polar Surface Area: 138.44 | Molecular Species: ACID | HBA: 8 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 9 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 4.16 | CX Basic pKa: 2.91 | CX LogP: 4.55 | CX LogD: 0.78 |
Aromatic Rings: 3 | Heavy Atoms: 34 | QED Weighted: 0.29 | Np Likeness Score: -0.04 |
1. Ragno R, Simeoni S, Castellano S, Vicidomini C, Mai A, Caroli A, Tramontano A, Bonaccini C, Trojer P, Bauer I, Brosch G, Sbardella G.. (2007) Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations., 50 (6): [PMID:17323938] [10.1021/jm061213n] |
2. Yamada Y, Fujii T, Ishijima R, Tachibana H, Yokoue N, Takasawa R, Tanuma S.. (2011) DR396, an apoptotic DNase γ inhibitor, attenuates high mobility group box 1 release from apoptotic cells., 19 (1): [PMID:21167721] [10.1016/j.bmc.2010.11.037] |
3. Kolarevic A, Yancheva D, Kocic G, Smelcerovic A.. (2014) Deoxyribonuclease inhibitors., 88 [PMID:25042005] [10.1016/j.ejmech.2014.07.040] |
4. Huang KW, Hsu KC, Chu LY, Yang JM, Yuan HS, Hsiao YY.. (2016) Identification of Inhibitors for the DEDDh Family of Exonucleases and a Unique Inhibition Mechanism by Crystal Structure Analysis of CRN-4 Bound with 2-Morpholin-4-ylethanesulfonate (MES)., 59 (17): [PMID:27529560] [10.1021/acs.jmedchem.6b00794] |
Source(1):